BENSALEM, Pa.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24NBRV&src=ctag” target=”_blank”gt;$NBRVlt;/agt; lt;a href=”https://twitter.com/hashtag/classaction?src=hash” target=”_blank”gt;#classactionlt;/agt;–Law Offices of Howard G. Smith reminds investors of the upcoming July
8, 2019 deadline to file a lead plaintiff motion in the class
action filed on behalf of investors who purchased Nabriva Therapeutics
plc (“Nabriva” or the “Company”) (NASDAQ: NBRV)
securities between November 1, 2018 and April 30, 2019, inclusive
(the “Class Period”).
Investors suffering losses on their Nabriva investments are encouraged
to contact the Law Offices of Howard G. Smith to discuss their legal
rights in this class action at 888-638-4847 or by email to [email protected].
On April 30, 2019, the Company revealed that it had received a Complete
Response Letter (“CRL”) from the U.S. Food and Drug Administration
(“FDA”) for its New Drug Application (“NDA”) for CONTEPO™ (fosfomycin)
for injection for the treatment of complicated urinary tract infections.
According to the CRL, the Company had to address certain “issues related
to facility inspections and manufacturing deficiencies at one of
Nabriva’s contract manufacturers” before the FDA would approve the NDA.
On this news, the Company’s share price fell $0.82 per share, more than
27%, to close at $2.17 per share on May 1, 2019, thereby injuring
investors.
The complaint filed in this class action alleges that the Registration
Statements were false and misleading and omitted to state material
adverse facts. Throughout the Class Period, Defendants made materially
false and/or misleading statements, as well as failed to disclose
material adverse facts about the Company’s business, operations, and
prospects. Specifically, Defendants failed to disclose to investors: (1)
that the Company’s manufacturers failed to meet good manufacturing
practices; (2) that these manufacturers would be subject to inspections
by the FDA in connection with the Company’s NDA; (3) that, as a result
of the manufacturing deficiencies, the Company’s NDA for CONTEPO was
unlikely to be approved by the FDA; and (4) that, as a result of the
foregoing, Defendants’ positive statements about the Company’s business,
operations, and prospects, were materially misleading and/or lacked a
reasonable basis.
If you purchased shares of Nabriva during the Class Period you may move
the Court no later than July 8, 2019 to ask the Court
to appoint you as lead plaintiff if you meet certain legal requirements.
To be a member of the class action you need not take any action at this
time; you may retain counsel of your choice or take no action and remain
an absent member of the class action. If you wish to learn more about
this class action, or if you have any questions concerning this
announcement or your rights or interests with respect to these matters,
please contact Howard G. Smith, Esquire, of Law Offices of Howard G.
Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by
telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected],
or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
Contacts
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
[email protected]
www.howardsmithlaw.com
